Inca00186

Description

Inca00186 is an experimental medication being studied by Incyte Corporation. It is currently in Phase 1 clinical trials, which means it is being tested for the first time in humans to determine its safety and how it is processed by the body. These trials are evaluating Inca00186 alone and in combination with other investigational drugs (INCB106385 and retifanlimab) in people with advanced solid tumors, including certain types of gastrointestinal cancers. The goal of these early trials is to find the right dose and understand how the drug works before potentially testing it in larger groups of patients. It is not yet approved for treating colorectal cancer or any other condition.

Mechanism of Action

Inca00186 is being investigated as a potential treatment for advanced solid tumors. The specific way it works (its mechanism of action) is still being studied in clinical trials. The trials are also looking at how Inca00186 affects the body (pharmacodynamics) and how the body processes the drug (pharmacokinetics). The trials specifically selected participants with CD8 T-cell-positive tumors, suggesting the drug might interact with the immune system.

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials